PetDx will present at the Stifel 2022 Jaws & Paws Conference
Business leaders will discuss market opportunities for liquid biopsy and early detection of cancer in dogs.
SAN DIEGO, May 27, 2022 /PRNewswire/ — PetDx® – The Liquid Biopsy Company for Pets™ is participating in the Stifel 2022 Jaws & Paws conference taking place in New York City on Wednesday, June 1, 2022. Founder and CEO of PetDx Daniel S. GrosuMD, MBA and Vice President of Strategy and Business Development Lauren HoltvoigtDVM, MBA, will present from 2:25 p.m. (EDT)immediately followed by a question-and-answer session.
Building on the recent publication of the landmark CANcer Detection in Dogs (CANDiD) study, the presentation will cover the market opportunity for liquid biopsy in canine cancer and review the development and commercialization of OncoK9®the company’s pioneering multi-cancer early detection (MCED) test for dogs using next-generation sequencing (NGS) of blood-derived DNA.
The live audio webcast of the presentation can be accessed at https://wsw.com/webcast/stifel72/petdx/2283408. An archived edition of the presentation will be available via the same link.
PetDx® – The Liquid Biopsy Company for Pets™ is a San Diegobased on molecular diagnostics and dedicated to unleashing the power of genomics to improve companion animal health. The company’s flagship product, OncoK9®, allows veterinarians to detect cancer in dogs with a simple blood test. As the first multi-cancer early detection (MCED) test, OncoK9 uses state-of-the-art genomic analysis that leverages next-generation sequencing (NGS) technology and proprietary bioinformatics algorithms, enabling veterinarians to deliver superior care to canine patients. To learn more, visit www.petdx.com and connect with us on Facebook, Instagram, LinkedIn and Twitter.
View original content to download multimedia: https://www.prnewswire.com/news-releases/petdx-to-present-at-stifel-2022-jaws–paws-conference-301556908.html